Clearside Biomedical(US:CLSD) Newsfilter·2024-07-22 16:00Core Insights - Clearside Biomedical, Inc. is hosting a virtual key opinion leader (KOL) event on July 24, 2024, focusing on the advancements in suprachoroidal drug delivery for retinal diseases, particularly neovascular age-related macular degeneration (wet AMD) [5][6]. Company Overview - Clearside Biomedical is a biopharmaceutical company that specializes in delivering therapies to the back of the eye through the suprachoroidal space (SCS) using its patented SCS Microinjector [9]. - The company's lead product, CLS-AX (axitinib injectable suspension), is currently in Phase 2b clinical testing for the treatment of wet AMD [4]. - Clearside's first approved product, XIPERE® (triamcinolone acetonide injectable suspension), is available in the U.S. through a commercial partner [4]. Clinical Development - The event will showcase the broad applicability of the SCS delivery method and its differentiation in the retinal treatment landscape, along with ongoing clinical programs and future development opportunities for Clearside [6]. - Clearside is developing a pipeline of small molecule product candidates for administration via its SCS Microinjector, indicating a commitment to expanding its therapeutic offerings [4]. Expert Participation - The event will feature presentations from retinal specialists, including Victor Chong, MD, MBA, Chief Medical Officer of Clearside, and other notable experts in the field [5][11][12].